» Articles » PMID: 18973179

Adrenocortical Carcinoma in the United States: Treatment Utilization and Prognostic Factors

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2008 Nov 1
PMID 18973179
Citations 202
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adrenocortical carcinoma (ACC) is a rare tumor with a relatively poor prognosis. The authors' objectives were to examine treatment utilization and factors associated with long-term survival after resection of ACC in a large, national, patient population.

Methods: Patients diagnosed with ACC from 1985 to 2005 were identified from the National Cancer Data Base (NCDB). Patient, tumor, treatment, and hospital factors associated with survival after resection were examined.

Results: For the current study, 3982 patients with ACC were identified. Median age at diagnosis was 55 years. Median tumor size was 13 cm. Of the patients with nodes examined, 26.5% had nodal metastases. Distant metastases were found on presentation in 21.6% of patients. A total of 57.4% of patients underwent surgical resection alone, whereas 16.0% underwent resection with adjuvant chemotherapy or radiation. A total of 19.4% had margin-positive resections. Treatment utilization remained unchanged from 1985 to 2005 (P = .28). Median follow-up was 24 months. Overall 5-year survival for all patients who underwent resection was 38.6% (median survival, 31.9 months). Multivariable analysis demonstrated a higher risk of death with increasing age, poorly differentiated tumors, involved margins, and nodal or distant metastases. Overall survival remained unchanged from 1985 to 2000 (P = .08).

Conclusions: ACC carries a poor prognosis for patients commonly presenting with large, locally invasive tumors, involved margins, and metastatic disease. Survival is not affected by size but is diminished with increasing age, poorly differentiated tumors, involved margins, and the presence of regional and distant disease. Identification of novel therapies may help to increase survival, which has remained unchanged over the last 20 years.

Citing Articles

Atypical clinical presentation of oncocytic adrenocortical carcinoma with decompensated metabolic syndrome and psychotic outbreak.

Picut B, Dubuis J, Demarchi M, Fournier I BMJ Case Rep. 2025; 18(3).

PMID: 40032570 PMC: 11880429. DOI: 10.1136/bcr-2024-262948.


Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma.

Ma S, Wu L, Ye L, Habra M, Balderrama-Brondani V, Wang W Endocrine. 2025; .

PMID: 39862362 DOI: 10.1007/s12020-025-04163-5.


An Unusual Case of Acute Abdomen With Jaundice.

Kakamba J, Wadhwani S, Bangolo A, Ngandu A, Bepouka B, Mbiso D Cureus. 2025; 16(12):e76155.

PMID: 39840167 PMC: 11745834. DOI: 10.7759/cureus.76155.


Early stage adrenocortical carcinoma-what contributes to poor prognosis after adrenalectomy? A retrospective cohort study.

Kwon D, Rah C, Kim B, Pak S, Cho J, Kim W Ann Surg Treat Res. 2024; 107(4):187-194.

PMID: 39416880 PMC: 11473319. DOI: 10.4174/astr.2024.107.4.187.


Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study.

Kaminski K, Blatkiewicz M, Szyszka M, Olechnowicz A, Komarowska H, Klimont A Int J Mol Sci. 2024; 25(16).

PMID: 39201408 PMC: 11354279. DOI: 10.3390/ijms25168721.